Keytruda® (pembrolizumab) – New indication
November 9, 2018 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
Download PDF
